These data are, therefore, broadly supportive of MET inhibitor-based therapy versus non-MET inhibitor regimens in patients with MET-aberrant NSCLC, although they should be interpreted with caution due to the small sample sizes involved and heterogeneity of the data. This evidence concerns the gene MET and non-small cell lung carcinoma.